QTRX Stock Overview
A life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 1/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Quanterix Corporation Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$13.41 |
52 Week High | US$29.70 |
52 Week Low | US$10.50 |
Beta | 1.39 |
11 Month Change | -13.82% |
3 Month Change | -17.12% |
1 Year Change | -47.18% |
33 Year Change | -73.73% |
5 Year Change | -48.18% |
Change since IPO | -23.24% |
Recent News & Updates
Quanterix Corporation: Still Struggling To Gain Traction
Aug 26Take Care Before Jumping Onto Quanterix Corporation (NASDAQ:QTRX) Even Though It's 26% Cheaper
Aug 15Recent updates
Quanterix Corporation: Still Struggling To Gain Traction
Aug 26Take Care Before Jumping Onto Quanterix Corporation (NASDAQ:QTRX) Even Though It's 26% Cheaper
Aug 15Positive Sentiment Still Eludes Quanterix Corporation (NASDAQ:QTRX) Following 25% Share Price Slump
Jun 27Quanterix Corporation's (NASDAQ:QTRX) 31% Cheaper Price Remains In Tune With Revenues
Apr 14Quanterix (NASDAQ:QTRX) Is In A Strong Position To Grow Its Business
Apr 05Quanterix Corporation (NASDAQ:QTRX) Yearly Results: Here's What Analysts Are Forecasting For This Year
Mar 03Here's Why We're Not Too Worried About Quanterix's (NASDAQ:QTRX) Cash Burn Situation
Oct 12We're Not Very Worried About Quanterix's (NASDAQ:QTRX) Cash Burn Rate
Jun 12We Think Quanterix (NASDAQ:QTRX) Can Afford To Drive Business Growth
Feb 10Quanterix Corporation: Selling For Less Than Cash Value
Sep 28We Think Quanterix (NASDAQ:QTRX) Can Afford To Drive Business Growth
Sep 23Quanterix stock gains after insider buys reported by CEO and CFO
Aug 17We're Hopeful That Quanterix (NASDAQ:QTRX) Will Use Its Cash Wisely
Mar 28Is Quanterix (NASDAQ:QTRX) A Risky Investment?
Feb 21Shareholder Returns
QTRX | US Life Sciences | US Market | |
---|---|---|---|
7D | 1.4% | -0.2% | 0.6% |
1Y | -47.2% | 2.3% | 22.9% |
Return vs Industry: QTRX underperformed the US Life Sciences industry which returned 3.8% over the past year.
Return vs Market: QTRX underperformed the US Market which returned 24.9% over the past year.
Price Volatility
QTRX volatility | |
---|---|
QTRX Average Weekly Movement | 10.8% |
Life Sciences Industry Average Movement | 8.8% |
Market Average Movement | 6.3% |
10% most volatile stocks in US Market | 15.1% |
10% least volatile stocks in US Market | 3.1% |
Stable Share Price: QTRX's share price has been volatile over the past 3 months.
Volatility Over Time: QTRX's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2007 | 441 | Masoud Toloue | www.quanterix.com |
Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays.
Quanterix Corporation Fundamentals Summary
QTRX fundamental statistics | |
---|---|
Market cap | US$525.03m |
Earnings (TTM) | -US$39.71m |
Revenue (TTM) | US$129.33m |
4.0x
P/S Ratio-13.0x
P/E RatioIs QTRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
QTRX income statement (TTM) | |
---|---|
Revenue | US$129.33m |
Cost of Revenue | US$55.06m |
Gross Profit | US$74.27m |
Other Expenses | US$113.98m |
Earnings | -US$39.71m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -1.03 |
Gross Margin | 57.42% |
Net Profit Margin | -30.71% |
Debt/Equity Ratio | 0% |
How did QTRX perform over the long term?
See historical performance and comparison